ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
70.73
+1.32 (+1.90%)
At close: 4:02PM EST

70.73 0.00 (0.00%)
After hours: 5:34PM EST

Stock chart is not supported by your current browser
Previous Close69.41
Open68.93
Bid70.01 x 800
Ask70.73 x 3100
Day's Range67.94 - 70.75
52 Week Range54.32 - 74.15
Volume6,802,348
Avg. Volume6,248,758
Market Cap124.225B
Beta (3Y Monthly)1.50
PE Ratio (TTM)142.03
EPS (TTM)0.50
Earnings DateJan 22, 2019 - Jan 28, 2019
Forward Dividend & Yield1.12 (1.54%)
Ex-Dividend Date2018-10-12
1y Target Est78.94
Trade prices are not sourced from all markets
  • Chartmaster says amid the market sell-off these are the b...
    CNBC Videos3 days ago

    Chartmaster says amid the market sell-off these are the b...

    Carter Worth, Cornerstone Macro, on quality bear-market stocks to buy. With CNBC's Joe Kernen and the Fast Money traders, Pete Najarian, Steve Grasso, Brian Kelly and Tim Seymour.

  • New Approvals Allow Chronic Pain Sufferers to Try Abbott's Non-Opioid Pain Therapy Before Getting Device Implant
    PR Newswire10 hours ago

    New Approvals Allow Chronic Pain Sufferers to Try Abbott's Non-Opioid Pain Therapy Before Getting Device Implant

    ABBOTT PARK, Ill., Nov. 15, 2018 /PRNewswire/ -- Abbott (ABT) today announced the launch of the new DRG Invisible Trial System, which is approved by the U.S. Food and Drug Administration (FDA) and received CE Mark in Europe. People battling complex chronic pain conditions can now use the DRG Invisible Trial System to try Abbott's dorsal root ganglion (DRG) stimulation—a clinically proven, non-opioid treatment option for targeted chronic pain management.

  • Abbott (ABT) Stock Moves -0.12%: What You Should Know
    Zacksyesterday

    Abbott (ABT) Stock Moves -0.12%: What You Should Know

    Abbott (ABT) closed at $69.41 in the latest trading session, marking a -0.12% move from the prior day.

  • Abbott Recommends Rejection of Below-Market Mini-Tender Offer by Baker Mills LLC
    PR Newswireyesterday

    Abbott Recommends Rejection of Below-Market Mini-Tender Offer by Baker Mills LLC

    ABBOTT PARK, Ill., Nov. 14, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing ...

  • Inside General Electric’s Healthcare Business Unit Spin-Off Plan
    Market Realist2 days ago

    Inside General Electric’s Healthcare Business Unit Spin-Off Plan

    As part of its major restructuring plan, General Electric (GE) intends to spin off its Healthcare segment and turn it into a standalone entity. The company has planned the spin-off in a manner that maximizes shareholder wealth.

  • Investing.com3 days ago

    Abbott Labs Falls 3%

    Investing.com - Abbott Labs (NYSE:ABT) fell by 3.04% to trade at $70.58 by 13:43 (18:43 GMT) on Monday on the NYSE exchange.

  • Surmodics' (SRDX) Q4 Earnings and Revenues Beat Estimates
    Zacks3 days ago

    Surmodics' (SRDX) Q4 Earnings and Revenues Beat Estimates

    Surmodics (SRDX) sees solid segmental performance in fiscal Q4; gains from alliance with Abbott.

  • Yacktman Asset Management Buys 4 Companies in 3rd Quarter
    GuruFocus.com6 days ago

    Yacktman Asset Management Buys 4 Companies in 3rd Quarter

    New buys include Tepper’s Micron Technology and Post-It notes parent 3M

  • Reuters6 days ago

    FOCUS-U.S. regulators snip red tape for medical devices to curb opioid crisis

    Laura Perryman expected her medical company, Stimwave Technologies Inc, would have to wait several years for its painkilling device to win U.S. approval as a treatment for chronic migraines. When President Donald Trump declared a public health emergency over the abuse of heavy-duty painkillers like oxycodone and hydrocodone, he ordered all government agencies to take action in response to the death of 70,000 Americans last year from drug overdoses. The FDA told Reuters it has received over 200 submissions from companies seeking a speedy approval process for their devices.

  • How Analysts View Alexion Stock
    Market Realist6 days ago

    How Analysts View Alexion Stock

    In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Alexion Pharmaceuticals stock is 1.83 with a target price of $163.29, implying an upside potential of 28.4% over Alexion Pharmaceuticals’ closing price of $127.18 on November 10, 2018.

  • Analyzing Alexion Pharmaceuticals’ Dicerna Collaboration
    Market Realist6 days ago

    Analyzing Alexion Pharmaceuticals’ Dicerna Collaboration

    In October 2018, Alexion Pharmaceuticals (ALXN) entered a collaboration with Dicerna Pharmaceuticals that provides Alexion exclusive worldwide licenses and development and commercial rights to two molecules for complement-mediated diseases along with an exclusive option for other molecules for two additional targets within the complement pathway. Under the collaboration, Alexion will make an upfront payment of $37.0 million and could be required to pay up to ~$625.0 million in milestone payments and royalties on product sales.

  • Abbott (ABT) Gains As Market Dips: What You Should Know
    Zacks7 days ago

    Abbott (ABT) Gains As Market Dips: What You Should Know

    In the latest trading session, Abbott (ABT) closed at $72.96, marking a +0.63% move from the previous day.

  • A Look at Alexion Pharmaceuticals’ Operational Performance
    Market Realist7 days ago

    A Look at Alexion Pharmaceuticals’ Operational Performance

    For fiscal 2018 and 2019, Alexion Pharmaceuticals’ gross margins are expected at 91.08% and 91.22%, respectively, as compared with gross margins of 91.95% for fiscal 2017. In comparison, fiscal 2018 gross margins for peers Abbott Laboratories (ABT), Amgen (AMGN), and Johnson & Johnson (JNJ) are expected at 59.29%, 85.73%, and 70.43%, respectively. Alexion Pharmaceuticals incurred selling, general, and administrative expenses of $258.7 million in the third quarter of 2018 as compared with $270.6 million in the third quarter of 2017.

  • How Alexion Is Positioned in November
    Market Realist7 days ago

    How Alexion Is Positioned in November

    Alexion Pharmaceuticals (ALXN), a global biopharmaceutical company, is a leader in complement inhibition and is focused on the therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. Alexion has brought to market the only approved complement inhibitor for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Further, the company has two enzyme replacement therapies for hypophosphatasia and lysosomal acid lipase deficiency.

  • Analyzing Alexion Pharmaceuticals’ Product Performance
    Market Realist7 days ago

    Analyzing Alexion Pharmaceuticals’ Product Performance

    Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma. Total Soliris sales increased from $755.4 million in the third quarter of 2017 to $888.0 million in the latest quarter. Its US sales increased from $307.6 million in the third quarter of 2017 to $404.5 million in the latest quarter. Its Europe sales increased from $248.4 million in the third quarter of 2017 to $262.1 million in the latest quarter.

  • Cramer's advice on investing during Washington gridlock: Buy fast growers
    CNBC8 days ago

    Cramer's advice on investing during Washington gridlock: Buy fast growers

    Jim Cramer recommends stocks like Amazon and Apple in the wake of the 2018 midterm elections, in which Democrats regained control of the House of Representatives.

  • 5 Income Stocks for Massive Payouts and Steady Growth
    InvestorPlace13 days ago

    5 Income Stocks for Massive Payouts and Steady Growth

    Although many investors like to follow equities for potential stock price increases, a large number also choose to focus on income stocks. The average S&P 500 stock dividend yield currently stands at just over 1.9%. Also, it allows for the long-term appreciation gained by investing in S&P 500 equities.

  • Abbott (ABT) Q3 Earnings Top Estimates
    Zacks13 days ago

    Abbott (ABT) Q3 Earnings Top Estimates

    Abbott (ABT) delivered earnings and revenue surprises of 1.35% and -0.12%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
    Zacks15 days ago

    Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

    Abbott (ABT) closed the most recent trading day at $69.30, moving +1.91% from the previous trading session.

  • Another Kleiner investor has just raised her own fund
    TechCrunch17 days ago

    Another Kleiner investor has just raised her own fund

    According to a newly processed SEC filing, the firm is called Define Ventures, and it has already locked down $50 million in capital commitments from a handful of investors. Chou O'Keefe had joined Kleiner Perkins in 2013 as a partner in its small life sciences group, to focus on digital health and connected devices. Before becoming a VC, she spent six years with Abbott Vascular, a division of the health care giant Abbott, first as a global product manager and later as a global marketing director.

  • Reuters20 days ago

    Abbott, AbbVie settle TriCor marketing case for $25 million

    The U.S. Justice Department on Friday announced the settlement, which resolves claims first raised in a whistleblower lawsuit filed in federal court in Philadelphia in 2009 by a former Abbott sales representative. AbbVie was spun out of Abbott in 2013.